Celcuity LLC (CELC) - Total Liabilities
Based on the latest financial reports, Celcuity LLC (CELC) has total liabilities worth $359.04 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Celcuity LLC to track the company's year-over-year net asset growth rate.
Celcuity LLC - Total Liabilities Trend (2015–2024)
This chart illustrates how Celcuity LLC's total liabilities have evolved over time, based on quarterly financial data.
Celcuity LLC Competitors by Total Liabilities
The table below lists competitors of Celcuity LLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Axos Financial Inc
NYSE:AX
|
USA | $24.64 Billion |
|
Murphy Oil Corporation
NYSE:MUR
|
USA | $4.80 Billion |
|
Bancolombia S.A
F:BXK
|
Germany | €322.44 Trillion |
|
Kumba Iron Ore Ltd
JSE:KIO
|
South Africa | ZAC31.70 Billion |
|
Yonyou Network Technology Co Ltd
SHG:600588
|
China | CN¥12.54 Billion |
|
MDA Ltd
TO:MDA
|
Canada | CA$1.95 Billion |
|
Hannon Armstrong Sustainable Infrastructure Capital Inc
NYSE:HASI
|
USA | $5.67 Billion |
|
Argo Investments Ltd
AU:ARG
|
Australia | AU$1.16 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Celcuity LLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CELC company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.75 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celcuity LLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celcuity LLC (2015–2024)
The table below shows the annual total liabilities of Celcuity LLC from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $129.50 Million | +151.71% |
| 2023-12-31 | $51.45 Million | +22.72% |
| 2022-12-31 | $41.93 Million | +143.81% |
| 2021-12-31 | $17.20 Million | +1270.76% |
| 2020-12-31 | $1.25 Million | +27.59% |
| 2019-12-31 | $983.23K | +44.12% |
| 2018-12-31 | $682.21K | +18.02% |
| 2017-12-31 | $578.05K | +29.79% |
| 2016-12-31 | $445.36K | +57.04% |
| 2015-12-31 | $283.60K | -- |
About Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2… Read more